The litigation centers on claims that the biotechnology firm concealed critical regulatory hurdles during the period leading up to its Biologics License Application (BLA). The complaint alleges that Replimune failed to resolve study design concerns previously raised by the FDA and relied on an early, limited dataset from only 40 patients—just 10% of the intended enrollment—to support its clinical claims.

Attorneys for the plaintiffs argue these omissions rendered the company's public statements regarding its operational prospects materially misleading. The lawsuit suggests that both the RPL-001-16 and RP1-104 programs suffered from deficiencies significant enough to warrant an FDA rejection, a reality not adequately communicated to shareholders. Those interested in participating can contact the Law Offices of Frank R. Cruz at 310-914-5007 or via their firm website to review their legal standing before the upcoming autumn deadline.